Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%

Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares traded down 5.3% during trading on Friday . The stock traded as low as $13.13 and last traded at $13.14. 3,490,392 shares were traded during mid-day trading, a decline of 67% from the average session volume of 10,592,093 shares. The stock had previously closed at $13.87.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TEVA shares. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Finally, HSBC began coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, December 18th. They issued a “buy” rating and a $13.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.78.

Teva Pharmaceutical Industries Stock Performance

The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The company’s 50-day moving average price is $13.41 and its two-hundred day moving average price is $11.15. The stock has a market cap of $14.91 billion, a PE ratio of -28.30, a PEG ratio of 1.61 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The company had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares in the company, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 390,738 shares of company stock valued at $5,132,766. Insiders own 0.62% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after purchasing an additional 1,494,814 shares in the last quarter. Phoenix Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 2.3% during the 3rd quarter. Phoenix Holdings Ltd. now owns 34,481,692 shares of the company’s stock valued at $351,713,000 after purchasing an additional 778,282 shares in the last quarter. Lingotto Investment Management LLP boosted its stake in shares of Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock valued at $359,738,000 after purchasing an additional 607,800 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Teva Pharmaceutical Industries by 7.1% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after purchasing an additional 2,188,212 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 6.9% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after purchasing an additional 1,860,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.